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Heart Failure With Normal
Left Ventricular Ejection Fraction
Micha T. Maeder, MD, David M. Kaye, MD, PHD
Melbourne, Australia
It is estimated that approximately 50% of the heart failure population has a normal left ventricular ejection frac-
tion, a complex broadly referred to as heart failure with normal left ventricular ejection fraction (HFNEF). While
these patients have been considered in epidemiologic studies and clinical trials to represent a single pool of pa-
tients, limited more detailed studies indicate that HFNEF patients are a very heterogeneous group, with a num-
ber of key pathophysiologic mechanisms. This review summarizes and critically analyzes available data on the
pathophysiology of HFNEF, placing it into context with a recently developed diagnostic algorithm. We evaluate
the utility of commonly applied echocardiographic measures and biomarkers and integrate mechanistic observa-
tions into potential future therapeutic directions. (J Am Coll Cardiol 2009;53:905–18) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.007i
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mt is now widely acknowledged that the clinical features of
eart failure (HF) can occur in patients with normal left
entricular ejection fraction (LVEF) (1–3), currently re-
erred to as heart failure with normal ejection fraction
HFNEF). In some cases the presentation can be as
ramatic as that in patients with low LVEF, for example in
atients admitted with acute pulmonary edema (2). In
onjunction with their clinical profile, stable HFNEF pa-
ients have been shown to display a similar physiologic and
eurohormonal phenotype to patients with HF and reduced
VEF, including impaired peak oxygen consumption, and
levated circulating neurohormones, including B-type na-
riuretic peptide (BNP) and norepinephrine (4). Taken
ogether, it is now generally accepted that an entity such as
FNEF exists (5). However, there is still much controversy
6–8) about the underlying pathophysiology. This high
evel of uncertainty is best reflected in the recent retreat
rom physiologic descriptors such as “diastolic HF” (9) to
he much more descriptive term “HFNEF” (10). The aim of
his review is to integrate clinical and pathophysiologic
spects of HFNEF, with a view to providing guidance in
elation to the diagnosis and management of HFNEF.
pidemiology
ata from the Mayo Clinic registry (11) and other studies
12) indicate that approximately 50% of patients with HF
ave a normal or near normal LVEF or fractional shorten-
rom the Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, and
eart Center, Alfred Hospital, Melbourne, Australia. Dr. Maeder is supported by the
wiss National Science Foundation (grant PBZHB-121007, Zürich, Switzerland).T
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ccepted December 8, 2008.ng, although a variety of cutoffs for normal values have been
pplied (12). Compared with patients with HF and reduced
VEF, individuals with HFNEF are typically older and
ore likely to be women, together with a higher likelihood
f hypertension (prevalence up to 88% [13]), obesity (prev-
lence of body mass index 30 kg/m2 typically approxi-
ately 40% [11,13]), renal failure, anemia, and atrial
brillation (11). In conjunction, the prevalence of diabetes
approximately 30% [11,13]) and coronary artery disease
approximately 40% to 50% [11–13]) are substantial, being
imilar to that in HF patients with impaired LVEF (11).
onsistent with the considerable symptomatic burden as-
ociated with HFNEF, the prognosis of patients with
FNEF also appears to be only marginally better than that
f patients with HF and reduced LVEF (11,14).
Interestingly, it has been consistently found that the
revalence of HFNEF is higher in community patients than
n referral patients with HF (45% vs. 55% [11,12]). Why
ight this be the case? Symptoms and signs of HF have
imited sensitivity and specificity, and while the inclusion of
chocardiographic and biomarker features may assist, con-
iderable scope remains for underdiagnosis or overdiagnosis.
urthermore, comorbidities including advanced age, pul-
onary disease, and obesity confound the diagnosis further
15). More broadly, the ability to extrapolate data generated
rom pathophysiologic studies to epidemiological studies is
onfounded by the application of various definitions. Specifi-
ally, for the latter type of studies, simply all patients with
he clinical diagnosis of HF (e.g., Framingham criteria [11])
nd an LVEF higher than the cutoff in the specific study
typically 50% [11]) were included, while cross-sectional
echanistic studies applied much more rigorous criteria.
hese studies typically excluded patients with “significant”
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HF With Normal LVEF March 17, 2009:905–18coronary artery disease (most often
clinically assessed, however [1,4,
16–19]; see discussion in the fol-
lowing text), hypertrophic cardio-
myopathy (4,16–19), and valvular
heart disease (1,4,16–19), in an
attempt to concentrate on a sub-
group of patients with “true”
HFNEF and similar pathophysi-
ology. On this basis, it is probable
that HFNEF patients represent a
heterogeneous population, which
is characterized only by the ab-
sence of an impaired LVEF,
whereas the group of patients with
“true” HFNEF is much smaller
than generally believed (Fig. 1).
Diabetic cardiomyopathy (20), al-
though also reported in conjunc-
tion with a dilated phenotype
and impaired LVEF (21) and
perhaps obesity cardiomyopathy
(22), would also be incorporated
within many of the epidemio-
logic studies of HFNEF, given
the high prevalence of diabetes
and obesity in the populations
examined.
Morphologic Features
and Function of the Left
Ventricle (LV) in HFNEF
In contrast to patients with HF
and impaired LVEF (typically
ith LV dilation, eccentric LV hypertrophy, and low
elative wall thickness), patients with HFNEF are charac-
erized more often with a nondilated LV, concentric LV
ypertrophy or at least concentric LV remodeling, and
ormal LVEF (Fig. 2) (23). A comparison of endomyocar-
ial biopsies revealed higher cardiomyocyte diameter and
igher myofibrillar density in patients with HFNEF com-
ared with those with HF and impaired LVEF, whereas
ollagen volume fraction was similar (24).
iastolic function. The traditional concept of HFNEF is
ased on sophisticated conductance catheter studies (16,25).
n contrast to patients with HF and impaired LVEF, where
V pressure–volume analysis typically reveals a less steep
lope of end-systolic LV pressure–volume relationship than
n subjects without HF, patients with HFNEF exhibit an
pward and leftward shifted end-diastolic pressure–volume
elationship, whereas the end-systolic pressure–volume re-
ationship (end-systolic elastance) is unaltered or even
teeper than in subjects without HF (26,27) (Fig. 2). In
heir landmark study, Zile et al. (16) have shown that
Abbreviations
and Acronyms
ATP  adenosine
triphosphate
  left ventricular passive
stiffness constant
BNP  B-type natriuretic
peptide
E=  early diastolic peak
mitral annulus velocity
assessed by pulse-waved
tissue Doppler
E/E=  transmitral peak
velocity during early
relaxation to early diastolic
peak mitral annulus
velocity
HF  heart failure
HFNEF  heart failure with
normal left ventricular
ejection fraction
LV  left ventricle/
ventricular
LVEDP  left ventricular
end-diastolic pressure
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
NYHA  New York Heart
Association
  time constant of the
isovolemic left ventricular
pressure declineatients with HFNEF (defined as symptoms of HF, LVEF H50%, and concentric LV hypertrophy or concentric LV
emodeling [25]) have abnormalities in both active LV
elaxation, as marked by a prolonged time constant of the
sovolemic pressure decline (), and LV stiffness, as reflected
y an increased LV passive stiffness constant  (Fig. 2,
able 1). It is proposed that the increased LV stiffness in
FNEF patients is associated with a marked increase in left
entricular end-diastolic pressure (LVEDP) and pulmonary
enous pressure after very small changes in LV end-diastolic
olumes, which leads to dyspnea during exercise and even
ulmonary edema (16,28). Exercise intolerance in these
atients is thought to be due to failure to increase cardiac
utput sufficiently during exercise due to impaired LV filling
nd an inability to use the Frank-Starling mechanism
1,16,28).
s diastolic dysfunction the only explanation? LV dia-
tolic dysfunction is a common finding in the elderly, in
articular among patients with hypertension (20). For
xample, in a cross-sectional study among 2,042 participants
29), the incidence of moderate-to-severe LV diastolic
ysfunction in the presence of an LVEF 50% was 5.6%.
owever, only approximately 1% of the study population
ad symptoms of HF and an LVEF 50%. Although
symptomatic advanced LV diastolic dysfunction also is
redictive of the future occurrence of HF (30), it is not clear
hy some patients with LV diastolic dysfunction have
FNEF and others are asymptomatic. Several studies have,
herefore, tried to identify echocardiographic features dis-
inguishing patients with LV hypertrophy and/or LV dia-
tolic dysfunction from those with LV hypertrophy/LV
iastolic dysfunction and HFNEF (Table 1).
Melenovsky et al. (19) compared 37 patients with HFNEF
previous hospitalization for pulmonary edema, LVEF50%)
ith 40 patients with hypertensive LV hypertrophy without
F and 56 control subjects (Table 1). HFNEF patients had a
igher LV mass index, more concentric LV geometry, higher
ransmitral peak velocity during early relaxation to early dia-
tolic peak mitral annulus velocity (E/E=) ratio, and larger left
trial volume than patients with hypertensive LV hypertrophy
nd control subjects. Most of these measurements distin-
uished HFNEF patients very well from control subjects but
ot from those with asymptomatic hypertensive LV hypertro-
hy (19). The product of LV mass index and left atrial volume
ad the highest accuracy for the prediction of HFNEF,
erhaps highlighting the proposition that left atrial size reflects
n integrative measure of the severity and chronicity of LV
iastolic dysfunction (31).
Lam et al. (32) (Table 1) have shown that despite similar
V mass index, HFNEF patients had more impaired LV
iastolic function (E/E= ratio), smaller LV end-diastolic
olume index, and smaller stroke volume index compared
ith patients with hypertension but without HF. Con-
ersely, others have found that HFNEF patients had a
arger LV end-diastolic volume index and larger stroke
olume index than patients with hypertension but without
F (Table 1) (33). In this and other studies, HFNEF
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March 17, 2009:905–18 HF With Normal LVEFatients also had more comorbidities including anemia and
enal dysfunction, leading to the suggestion that volume
verload rather than an intrinsic abnormality of LV dia-
tolic function may contribute to the pathophysiology of
FNEF (33).
V systolic function. Historically, the description of HFNEF
atients has been confused by the use of various terms
ncluding “diastolic HF” and “HF with preserved systolic
unction,” the latter term giving rise to considerable debate. By
efinition, the LVEF in patients with HFNEF is considered
normal,” although the distinction between normal and abnor-
al has varied considerably from 40% to 50% (28). However,
he value of LVEF as a measure of LV systolic function in the
redominantly elderly HFNEF population has been ques-
ioned (34), given, among other limitations, its considerable
oad dependence. The recognition that LVEF is an imprecise
easure of LV systolic function has led to a range of more
ensitive tools being applied in patients with HFNEF. Studies
sing invasive conductance catheterization to derive pressure-
olume loops have tended to suggest that LV end-systolic
lastance is normal or slightly increased, often in the setting of
ncreased arterial elastance suggesting ultimately that “contrac-
ility” is normal (26,27). Recently developed echocardiographic
easures of systolic function have also provided additional
nformation while introducing further complexity. Several
tudies have shown that the annular peak systolic velocity
Figure 1 Scheme Illustrating the Differential Diagnoses to the
It is suggested that a certain proportion of patients given the clinical diagnosis of
do not have symptoms arising from primary ventricular dysfunction. Within the grou
normal left ventricular ejection fraction (HFNEF) in the sense that the term has bee
nostic criteria (Fig. 3) (10). CMP  cardiomyopathy; HOCM  hypertrophic obstrucssessed by tissue Doppler imaging is reduced in HFNEF aatients (35,36), while one more recent study suggested that
V twist is preserved in HFNEF patients albeit in the presence
f reduced longitudinal and radial strain (37). One confound-
ng issue in the application of “single point” echocardiographic
easures such as strain is their load dependence, which is not
ccounted for in the presence of potential alterations in both
re-load and afterload in HFNEF. Thus, it is still controversial
hether LV systolic function is normal in HFNEF. More
mportantly, however, the simple separation of the cardiac cycle
nto systolic and diastolic phases is not well justified (38,39),
iven various inter-related processes including the influence of
ystole on subsequent filling and the influence of passive
entricular properties on systolic function.
entriculovascular coupling in HFNEF. Although much
f the recent emphasis in research has aimed at determining
he mechanisms that contribute to ventricular dysfunction in
FNEF, it is increasingly evident that concomitant abnor-
alities in arterial mechanics play a major role (40). One
ntegrated measure of arterial stiffness, the effective arterial
lastance, is a global measure of arterial stiffness, which can
elatively simply be determined as the ratio of LV end-
ystolic pressure/stroke volume (40) and is typically elevated
n HFNEF patients. However, both end-systolic elastance
nd arterial elastance are typically elevated in HFNEF,
eading to only a modest reduction in the ratio of arterial
lastance/end-systolic elastance, similar to that observed in
rome of HFNEF
failure in the presence of a left ventricular ejection fraction (LVEF) 50% likely
atients with heart failure and LVEF 50%, only a subgroup has heart failure with
ned by pathophysiology studies (Tables 1 and 2) and the recently proposed diag-
rdiomyopathy; PAHT  pulmonary arterial hypertension.Synd
heart
p of p
n defi
tive cage-matched hypertensives (27). While this observation
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HF With Normal LVEF March 17, 2009:905–18ay seem counterintuitive, it has been suggested that
ombined ventricular-arterial stiffening contributes to the
yndrome of HFNEF by a number of mechanisms, as
ecently extensively reviewed elsewhere (40,41): 1) exagger-
ted increase in systolic blood pressure after small increases
n LV end-diastolic volume; 2) a marked increase in systolic
lood pressure after a further increase in arterial elastance in
he presence of a high end-systolic elastance; 3) limited
ystolic reserve due to high baseline end-systolic elastance;
Figure 2 Comparison of the Characteristics of LV Morphology a
The pressure-volume loops highlight that in patients with heart failure (HF) and imp
elastance), which is obtained by recording pressure-volume loops at different pre-l
(dashed lines), and the loops are shifted toward larger volumes. In contrast, the e
HFNEF patients typically exhibit an end-diastolic pressure–volume relationship that
constant; BNP  B-type natriuretic peptide; dp/dt  rate of isovolemic increase in
early diastolic peak mitral annulus velocity; LV  left ventricular; LVEDP  left ven
NT-proBNP  N-terminal pro-B-type natriuretic peptide; other abbreviations as in Fi) increased cardiac work to deliver a given cardiac output; ind 5) a direct influence of high arterial elastance on LV
iastolic function (impaired relaxation). The first 2 mecha-
isms would also explain the sensitivity of these patients to
verdiuresis and aggressive vasodilator therapy.
ole of Atrial Fibrillation
he prevalence of atrial fibrillation is considerable in both
pidemiological studies (30% to 40% [11,12]) and random-
unction in Patients With HF and Reduced LVEF and HFNEF
LVEF, the slope of the end-systolic pressure–volume relationship (end-systolic
vels, is typically less steep (solid lines) than in people with normal hearts
tolic pressure–volume relationship is steeper or normal in HFNEF. However,
fted upwards and to the left (solid lines) (dashed lines  normal).   stiffness
entricular pressure; E/E=  transmitral peak velocity during early relaxation to
r end-diastolic pressure; LVEDV  left ventricular end-diastolic volume;
.nd F
aired
oad le
nd-sys
is shi
left v
tricula
gure 1zed controlled trials of HF with normal LVEF (20% to
Selected Studies Investigating Mechanisms Underlying HFNEF: Studies at Rest
Table 1 Selected Studies Investigating Mechanisms Underlying HFNEF: Studies at Rest
Mechanism Study Group
Age
(yrs) Race
BMI
(kg/m
2
)
Diabetes
(%)
CAD
(%) LVMI
LVEF
(%) E/E= Key Data: Cases vs. Control Subjects
LV relaxation2
LV stiffness1 (16)
HFNEF (n  47) 59 12 NA NA NA Excluded Concentric LVH/
LV remodeling
50% NA LVEDP higher in HFNEF: 25  6 mm Hg vs. 8  2 mm Hg
Control subjects
(chest pain,
n  10)
58 16 NA NA NA Excluded
(angiography)
NA 50% NA LVEDV smaller in HFNEF: 103  22 ml vs. 115  9 ml
 longer in HFNEF: 59  14 ms vs. 35  10 ms
 higher in HFNEF: 0.03  0.01 vs. 0.01  0.01
LVH1/LA dilation1 (19) HFNEF (n  37) 65 10 76% African
American
37 8 60 42 81 23 g/m2.7 65 10 15 5 Maximal LA volume higher in HFNEF: 84  26 ml vs.
60  16 ml
Control subjects
(LVH, n  40)
67 10 73% African
American
31 6 35 10 58 12 g/m2.7 67 10 11 5 Maximal LA volume  LVMI higher in HFNEF: 6,989  2,974
ml  g/m2.7 vs. 3,516  1,367 ml  g/m2.7
LV volume2 (32) HFNEF (n  244) 76 (22–99) NA 32 20 37 53 102 29 g/m2 62 6 18 10 LVEDVI lower in HFNEF: 61 16 ml/m2 vs. 65 14 ml/m2
Control subjects
(HTN, n  719)
66 (46–91) NA 30 6 11 16 100 23 g/m2 65 6 9 3 SVI lower in HFNEF: 42 10 ml/m2 vs. 46 10 ml/m2
LV relaxation (E=) slower in HFNEF: 6.0 2.1 cm/s vs.
7.7 3.9 cm/s
Volume overload (33) HFNEF (n  167) 76 7 65% Caucasian 27 6 30 58 98 34 g/m2 72 7 NA LVEDVI higher in HFNEF: 69 22 ml/m2 vs. 62  14 ml/m2
Control subjects
(HTN, n  2,184)
73 6 78% Caucasian 27 5 20 20 87 24 g/m2 74 7 NA SVI higher in HFNEF: 50  14 ml/m2 vs. 46  11 ml/m2
eGFR lower in HFNEF: 56  22 ml/min vs. 61  20 ml/min
Anemia* more prevalent in HFNEF: 19% vs. 8%
Data are given as mean  SD or median (range). *Hemoglobin 12 g/dl in women and 13 g/dl in men.
 left ventricular passive stiffness constant; BMI body mass index; CAD coronary artery disease; E= early diastolic peakmitral annulus velocity; E/E= transmitral peak velocity during early relaxation to early diastolic peakmitral annulus velocity; eGFR estimated
glomerular filtration rate; HFNEF heart failure with normal ejection fraction; HTN  hypertension; LA left atrial; LV left ventricular; LVEDP left ventricular end-diastolic pressure; LVEDV(I) left ventricular end-diastolic volume (index); LVEF  left ventricular ejection
fraction; LVH  left ventricular hypertrophy; LVMI  left ventricular mass index; NA  not available; SVI  stroke volume index;   time constant of the left ventricular isovolemic pressure decline.
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HF With Normal LVEF March 17, 2009:905–180% [13,42,43]). Fung et al. (44) reported that HFNEF
atients (LVEF 50%) with atrial fibrillation (29%) had
orse functional class and quality of life, lower 6-min
alking distance, and larger left atrial diameter than those
ithout atrial fibrillation. In the CHARM (Candesartan in
eart Failure) study, atrial fibrillation was associated with
dverse cardiovascular outcomes irrespective of baseline
VEF (45). High heart rate, loss of atrial systole, irregular
ycle length with implications of the Frank-Starling mech-
nism, and its episodic nature in many patients have been
iscussed as a mechanism by which atrial fibrillation confers
worsened clinical status in HFNEF (44).
Given that echocardiographic assessment of LV diastolic
unction is extremely challenging in atrial fibrillation (46),
hese patients have been excluded from many recent patho-
hysiology studies on HFNEF (16–19). Interestingly, Fung
t al. (44) found similar E/E= ratios in HFNEF patients
ith and without atrial fibrillation (21.4 vs. 20.2) but larger
eft atrial size in those with atrial fibrillation. In the study by
elenovsky et al. (19), left atrial emptying fraction was
ower in HFNEF patients than in control subjects (patients
ith hypertensive LV hypertrophy), and during handgrip
xercise, late diastolic annular tissue velocity remained
irtually unchanged in HFNEF patients but increased in
ontrol subjects (5% vs. 35% change). Thus, HFNEF
atients with left atrial enlargement may be particularly
ymptom prone on the basis of reduced atrial emptying and
n increased risk of paroxysmal atrial fibrillation (47).
ole of Coronary Artery Disease
n patients with coronary artery disease, provocation of
yocardial ischemia by rapid atrial pacing results in an
pward shift of the diastolic LV pressure–volume relation-
hip (48). Ischemia affects early diastole by prolongation of
(48–50), which is reversed after removal of the ischemic
urden by coronary bypass grafting (50), whereas the effects
n passive stiffness are less clear. Given the high risk profile
or, or high prevalence of, documented coronary artery
isease, and the fact that in none of the epidemiological
tudies and randomized controlled trials evaluating treat-
ent for HFNEF have attempts been made to exclude
yocardial ischemia with a sensitive method, it is tempting
o speculate that a considerable number of patients with
typical presentation of myocardial ischemia (silent or dys-
nea) has been labeled as HFNEF. This suspicion is
upported by a study reporting a 15% incidence of hospital
dmission due to unstable angina in patients previously
iagnosed with HFNEF during a median follow-up of 38
onths (51).
esponse to Exercise
eak oxygen consumption in HFNEF patients is signifi-
antly reduced if compared with healthy control subjects i4,52) or asymptomatic patients with hypertensive LV
ypertrophy (18). Kitzman et al. (4) found a similarly
mpaired peak oxygen consumption in patients with
FNEF and those with HF and impaired LVEF (14.2
l/kg/min vs. 13.1 ml/kg/min), although the higher pro-
ortion of women in the HFNEF (86% vs. 35%) group
akes interpretation of absolute values for peak oxygen
onsumption difficult.
Comparatively few studies have evaluated the hemody-
amic response to aerobic exercise. In a comprehensive
tudy using upright bicycle exercise testing with simulta-
eous right heart catheterization and serial radionuclide
entriculography (1), cardiac index, stroke volume index,
nd LV end-diastolic volume index at rest did not differ
etween HFNEF patients and control subjects but were
ower in patients with HFNEF at peak exercise, resulting in
markedly lower peak oxygen consumption (Table 2).
ulmonary capillary wedge pressure at rest was somewhat
igher in HFNEF patients compared with control subjects
ut much higher at peak exercise (Table 2). These findings
ere interpreted as impaired LV filling on the one hand and
ailure to use the Frank-Starling mechanism properly on the
ther hand (1). The HFNEF group also had a diminished
rteriovenous oxygen difference, which led to the suggestion
hat “peripheral factors” such as the leg vasculature or the
usculature might contribute to exercise intolerance in
FNEF (1).
In a study by Borlaug et al. (18), HFNEF patients
with a history of pulmonary edema and LVEF 50%)
howed a lower increase in heart rate, a lower decrease in
ystemic vascular resistance index, and a lower increase in
ardiac index during exercise when compared with the
ontrol group (Table 2). Notably, LV end-diastolic volume
ndex did not decrease in either group during exercise but
ncreased to a similar degree. This observation led to the
uggestion that the chronotropic and vasodilatory reserve in
FNEF patients is diminished (18). Notably, an impaired
hronotropic response in patients with HFNEF had also
een reported by others (1,17).
Westermann et al. (17) compared hemodynamics at
est, during right ventricular pacing at 120 beats/min,
nd during handgrip exercise in 70 comparatively young
FNEF patients and 20 control subjects (Table 2). At
est, LVEDP, , and  were higher in HFNEF patients
s compared with that in control subjects. During pacing,
and LVEDP decreased in both groups, and the median
VEDP in the HFNEF group even became normal (8
m Hg), whereas  remained unchanged in both groups.
owever, in contrast to control subjects, LV end-
iastolic volume and stroke volume in HFNEF patients
ecreased during pacing, which was interpreted as the
anifestation of increased stiffness during high heart
ates. However, handgrip exercise was associated with a
arked increase in LVEDP in HFNEF patients but notn control subjects, and LV end-diastolic volumes did not
Selected Studies Investigating Mechanisms Underlying HFNEF: Studies Including Exercise
Table 2 Selected Studies Investigating Mechanisms Underlying HFNEF: Studies Including Exercise
Mechanism Study Group
Age
(yrs) Race
BMI
(kg/m2)
Diabetes
(%) CAD LVMI
LVEF
(%)
Peak VO2
(ml/kg/min) Key Data: Cases vs. Control Subjects
LV filling2, failure
of Frank-Starling
mechanism,
chronotropic
incompetence (1)
HFNEF (n  7) 65 12 NA NA 29 Excluded
(angiography)
107 27 g/m2 58 11.6 4.0 Lower peak heart rate in HFNEF:
126  27 beats/min vs.
154  11 beats/min
Healthy control
subjects
(n  10)
61 8 NA NA 0 Excluded
(exercise test)
NA 50 22.7 6.1 Lower peak exercise LVEDVI in HFNEF: 56
 14 ml/m2 vs.
68  12 ml/m2
Lower peak exercise SVI in HFNEF:
34  9 ml/m2 vs.
46  7 ml/m2
Higher peak exercise PCWP in HFNEF:
25.7  9.1 mm Hg vs.
7.1  4.4 mm Hg
Chronotropic
incompetence,
vasodilatory
reserve2 (18)
HFNEF (n  17) 65 9 71% African
American
37 8 “Most” NA 75 24 g/m2.7 73 7 9.0 3.4 Lower increase in heart rate
in HFNEF: peak exercise:
18 beats/min vs. 48 beats/min*
Control subjects
(LVH, n  19)
65 9 78% African
American
31 6 “Most” NA 60 16 g/m2.7 70 8 14.4 3.4 Smaller reduction in SVRI in HFNEF:
peak exercise: 600 dyne  s 
cm5  m2 vs. 1,100 dyne  s 
cm5  m2*
LV stiffness1 (17) HFNEF (n  70) 58 (52–64) 100% Caucasian 28 (23–32) 17 Excluded
(history)
128 (109–135) g/m2 65 (59–73) NA; 128 W Rest ¡ pacing 120 beats/min
Control subjects
(chest pain,
n  20)
55 (46–60) 100% Caucasian 26 (23–28) 10 Excluded
(angiography)
95 (81–99) g/m2 65 (62–75) NA; 184 W
LVEDP2 in HFNEF and control
subjects: 16.1¡7.7 mm Hg vs.
5.6¡4.5 mm Hg
2 in HFNEF and control subjects:
54¡43 ms vs. 41¡36 ms
LVEDV2 in HFNEF: 151¡109 ml vs.
158¡169 ml
SV2 in HFNEF: 94¡72 ml vs.
109¡122 ml
Rest¡ handgrip exercise
Lower increase in heart rate in HFNEF:
71¡103 beats/min vs. 69¡121
beats/min
LVEDP1 only in HFNEF: 15¡23 mm Hg
vs. 6¡7 mm Hg
LVEDV unchanged in HFNEF/control
subjects: 148¡152 ml vs.
154¡159 ml
Data are given as mean  SD or median (interquartile range). *Exact data not given in the study; they were estimated from the figure.
PCWP  pulmonary capillary wedge pressure; SVRI  systemic vascular resistance index; VO2  oxygen consumption; other abbreviations as in Table 1.
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HF With Normal LVEF March 17, 2009:905–18ecrease in either group. Notably,  was unaffected in
oth groups (17).
It has been criticized (8) that the hemodynamic re-
ponse to pacing in control subjects in this study did not
orrespond to more typical physiologic responses. Pacing
n healthy humans has been reported to result in a
ecrease in LV end-diastolic volume and stroke volume
nd thereby a blunted cardiac output response (53),
hich is interpreted as a physiologic response in an
ttempt to minimize the increase in myocardial oxygen
emand resulting from the increase in heart rate (8).
hus, the decrease in LV end-diastolic volume and stroke
olume in HFNEF patients during pacing is difficult to
nterpret, particularly in the context of a normal LVEDP
8). Importantly, during the more physiologic form of
xercise (handgrip), there was no change in LV end-
iastolic volume. Thus, we are faced with conflicting data
rom small studies concerning the hemodynamic response
o exercise in HFNEF, which in part might be explained
y differences in study methodology and populations
tudied (Table 2).
iagnosis of HFNEF
rinciple of the diagnosis of HFNEF. In 2000, Vasan
nd Levy (9) suggested the following criteria for the
iagnosis of HFNEF or “diastolic HF,” respectively. A
atient could be definitely diagnosed with “diastolic HF” if
he following 3 criteria were fulfilled: 1) symptoms and signs
f HF; 2) LVEF 50% within 72 h of the HF event; and
) evidence of LV diastolic dysfunction by abnormal LV
elaxation/filling/distensibility indexes on cardiac catheter-
zation. A probable diagnosis could be obtained if the
ormer 2 criteria were fulfilled but if there was no informa-
ion on LV diastolic function, and the diagnosis was still
ossible in a patient with symptoms and signs of HF, LVEF
50% but not within 72 h of the HF event, and lack of
nformation on LV diastolic function. This approach was
ased on the assumption that echocardiography was not a
eliable tool to assess LV diastolic function (9).
In 2007, the European Working Group on HFNEF
roposed a new diagnostic algorithm (10), which is based on
he concept of Vasan and Levy (9) but includes new insights
nto the utility of noninvasive tools to estimate LV filling
ressures. The principle of this algorithm is displayed in
igure 3. Three conditions must be fulfilled for the diag-
osis of HFNEF: 1) symptoms and signs of HF; 2) LVEF
50% in a nondilated LV (LV end-diastolic volume 97
l/m2, which is the cutoff between a moderately and
everely abnormal LV volume index according to the Amer-
can Society of Echocardiography recommendations for
hamber quantification [54]); and 3) evidence of elevated
V filling pressures. Three ways to diagnose elevated LV
lling pressures have been proposed: first, invasive measure-
ents; second, unequivocal tissue Doppler imaging find-ngs; and third, a combination of elevated natriuretic pep- aides and echocardiographic indexes of LV diastolic
unction/LV filling pressures (10). The utility of these tools
ill be discussed in the following paragraphs.
nvasive diagnostics. Apart from prolonged  and in-
reased , which require sophisticated measurement (not
sually performed in routine clinical practice), elevated
VEDP or pulmonary capillary wedge pressure are also
uggested to be appropriate for the diagnosis of HFNEF in
he presence of HF symptoms and an LVEF 50% (10). It
hould be noted that both HFNEF and a constrictive
hysiology (which should be differentiated from HFNEF
10]) may present with the latter constellation. This differ-
ntiation would be possible using tissue Doppler imaging as E=
s typically low in HFNEF but normal in constriction (55).
chocardiography. Conventional Doppler echocardiogra-
hy using mitral inflow and pulmonary venous flow patterns
learly has limitations with respect to the assessment of LV
iastolic function, which is best illustrated by the data
rom the echocardiography substudy of the CHARM-
RESERVED (Candesartan in Heart Failure–Preserved)
rial (56), where those reading the echocardiograms were
ble to differentiate a normal from a pseudonormal mitral
nflow pattern in only 14% of patients. In the other 86% of
ases, a pseudonormal pattern was diagnosed based on an
levated N-terminal pro-B-type natriuretic peptide (NT-
roBNP) level (56), which relies on the optimistic assump-
ion that NT-proBNP can accurately differentiate a normal
rom a pseudonormal inflow pattern. Therefore, a diagnosis
f HFNEF based on Doppler echocardiography alone is not
ossible according to the new algorithm (10). Currently, the
ost sensitive and widely available echocardiographic tech-
ique for the assessment of LV diastolic function is that of
issue Doppler imaging. Whereas the ratio of early to late
iastolic peak mitral inflow velocities exhibits a J-shaped
elationship with LVEDP, tissue Doppler-derived in-
ramyocardial velocities continuously decline from normal
o advanced LV diastolic dysfunction. As a consequence, E=
ecreases and the E/E= ratio continuously increases with
dvanced LV diastolic dysfunction.
Nonetheless, the limitations to this technique in the
ontext of HFNEF should be noted. In the original study by
mmen et al. (57), the correlation quotient between the
/E= ratio (E= measured at the medial mitral annulus) and
he mean LV diastolic pressure was 0.60 for patients with
VEF 50% but only 0.47 for those with LVEF 50%.
owever, all patients with an E/E= ratio 15 had a mean
iastolic LV pressure 12 mm Hg. Thus, the new algo-
ithm suggests an E/E= ratio 15 for the diagnosis of
levated LV filling pressure and thus HFNEF in a patient
ith typical symptoms and signs of HF and LVEF 50%.
n E/E= ratio between 8 and 15, however, was associated
ith a very wide range of mean LV diastolic pressures in the
tudy by Ommen et al. (57), and, thus, further measure-
ents are suggested in a patient with suspected HFNEFnd an E/E= ratio between 8 and 15 (10).
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March 17, 2009:905–18 HF With Normal LVEFData supporting this approach in the setting of possible
FNEF are very sparse and basically rely on 1 study (58).
mong 43 patients with HFNEF and 12 control subjects
ithout cardiac disease, Kasner et al. (58) found a strong
orrelation between E/E= and LVEDP (r  0.71) but only
oderate correlations between E/E= and  (r  0.34), and
(r  0.53). The area under the receiver-operator charac-
eristic curve for the invasive diagnosis of HFNEF using
ressure-volume loop analysis was reported as 0.91. Of note,
his applied only for E/E= assessed at the lateral annulus,
nd E/E= values measured at the medial annulus did not
ifferentiate HFNEF patients from control subjects (58). In
he previously mentioned study by Melenovsky et al. (19),
owever, the area under the receiver-operator characteristic
urve for the E/E= ratio (averaged from medial and lateral
nnulus) for the prediction of HFNEF (defined as a history
f pulmonary edema and LVEF 50%) was only 0.69.
alues for E= at the lateral annulus are generally higher than at
he medial annulus, resulting in lower E/E= ratios at the lateral
nnulus (59). Thus, E/E= cutoffs derived from studies using the
Figure 3 Principles of the Algorithm Proposed for the Diagnosis
by the Working Group of the European Society of Card
b  left ventricular passive stiffness; DCT  deceleration time; E/A  ratio of early to
index; LVH  left ventricular hypertrophy; mPCWP  mean pulmonary capillary wedge
imaging; other abbreviations as in Figures 1 and 2. Adapted from Paulus et al. (10), wedial or the lateral annulus are not directly comparable. tThe E/E= ratio also seems to reflect LV filling pressure
uring exercise. A study among 37 unselected patients (the
ajority with preserved LV systolic function) undergoing
oth left heart catheterization with measurement of
VEDP and simultaneous echocardiography revealed that
/E= measured at the medial annulus was related to LVEDP
oth at rest and during exercise. However, the correlation
etween E/E= and LVEDP directly after exercise was some-
hat worse (r  0.59) than at rest (r  0.67) (60).
atriuretic peptides. BNP and the N-terminal part of its
recursor peptide, NT-proBNP, are established tools for
he exclusion of possible HF in patients presenting to the
mergency room with dyspnea of unclear origin (61,62), and
lthough data are more sparse, also in outpatients presenting
ith symptoms possibly attributable to HF (63,64). Nota-
ly, the majority of data about BNP and NT-proBNP for
he evaluation of patients with possible HF was derived
rom studies with patients with HF and impaired LVEF.
mong patients with preserved LVEF but not necessarily
F, BNP and NT-proBNP levels were found to be related
FNEF
y
iastolic peak mitral inflow velocities; LVEDVI  left ventricular end-diastolic volume
re;   time constant of the isovolemic pressure decline; TDI  tissue Doppler
mission from Oxford press.of H
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ith pero the severity of LV diastolic dysfunction (61,65), and
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HF With Normal LVEF March 17, 2009:905–18ased on these data, NT-proBNP has even been used to
istinguish a normal from a “pseudonormal” (LVEDP
levated) LV filling pattern (56).
The working group has proposed a BNP level 200
g/ml or an NT-proBNP level 220 pg/ml to confirm the
iagnosis of HFNEF in patients with symptoms of HF,
VEF 50%, and an ambiguous E/E= value between 8 and
5 (10). This NT-proBNP cutoff was derived from a
arefully combined echocardiography and invasive study
mong patients with both LV diastolic dysfunction as
ssessed by Doppler echocardiography and symptoms of HF
nd a control group without LV diastolic dysfunction or
ymptoms (65). The area under the receiver-operator char-
cteristic curve for NT-proBNP to predict HFNEF was
.83. However, the study group was significantly younger
age 51 19 years), and the proportion of women was lower
46%) than in other typical HFNEF populations. Given
hat female sex and older age are associated with higher
T-proBNP levels (66), the proposed cutoffs might be too
ow and thus too unspecific to differentiate elderly patients
ith and without HFNEF. Second, the BNP cutoff of
200 pg/ml was derived from a study in emergency
epartment patients (67) and may, therefore, not be more
roadly representative. These limitations were also acknowl-
dged by the working group, who recommended that BNP
nd NT-proBNP should be mainly used for the exclusion of
FNEF, with upper limits for exclusion of 100 and 120
g/ml, respectively (10).
reatment
iven that the mechanisms underlying HFNEF are still
nder debate, it is not surprising that there is no evidence-
ased treatment for patients with HFNEF. However, LV
ypertrophy seems to be an important target for prevention
f HF. A recent analysis of a subgroup from the Cardiovas-
ular Healthy Study without a history of previous myocar-
ial infarction identified LV hypertrophy as a predictor for
he future development of HF independent of age, sex,
besity, diabetes, and hypertension (68). In addition, regres-
ion of the Cornell product under antihypertensive therapy
as been found to be associated with less hospitalization for
F in hypertensive patients (69). Aggressive treatment of
ypertension and diabetes is recommended to prevent HF
y guidelines (5), and it may also reduce the incidence of
FNEF.
For the treatment of HFNEF, guidelines recommend
lood pressure control (class I, level A) (5). All other
ecommendations are evidence level C. Given the high
revalence of diabetes and LV hypertrophy, there is a
ompelling indication for angiotensin-converting enzyme
nhibitors or angiotensin receptor blockers in many patients.
owever, the 3 trials evaluating the angiotensin receptor
lockers candesartan (the CHARM-PRESERVED trial
42]) and irbesartan (the I-PRESERVED [Irbesartan in
eart Failure With Preserved Ejection Fraction Study] trial b70]) and the angiotensin-converting enzyme inhibitor per-
ndopril (the PEP-CHF [Perindopril for Elderly People
ith Chronic Heart Failure] trial [43]) in patients with
FNEF did not reveal a survival benefit when compared
ith that seen in placebo. This might, however, have been
t least in part due to patient selection: the CHARM-
RESERVED study included patients with the clinical
iagnosis of HF and an LVEF 40%. Notably, in the
chocardiographic substudy, only 67% had evidence of LV
iastolic dysfunction (56). In the PEP-CHF study (43), an
VEF of more than approximately 40% (defined by wall
otion score), evidence of LV diastolic dysfunction based
n Doppler echocardiography (not tissue Doppler), and
linical criteria had to be fulfilled. Very recently, the
-PRESERVED trial (70) evaluated the use of irbesartan in
atients age 60 years with an LVEF 45% and symptoms
f HF (New York Heart Association [NYHA] functional
lass II to IV with prior hospitalization) or NYHA func-
ional class III or IV symptoms in the absence of prior
ospitalization. Furthermore, 1 of the following features
as also required for inclusion: pulmonary congestion in
hest X-ray, LV hypertrophy (electrocardiogram or echo-
ardiogram), left bundle branch block, or left atrial enlarge-
ent (echocardiography) in absence of atrial fibrillation
70). Patients were overall very symptomatic (almost 80% in
YHA functional class III or IV) and had a high event rate.
owever, despite a more pronounced reduction in systolic
3.6 mm Hg vs. 0.2 mm Hg) and diastolic (2.1 mm Hg vs.
.2 mm Hg) blood pressure, there were no differences in the
rimary end point (death from any cause or hospitalization
or cardiovascular causes) between the irbesartan and pla-
ebo groups (70). Detailed tissue Doppler studies of dia-
tolic function were not included in the I-PRESERVED
tudy. A number of reasons may have contributed to the
egative study result, including multifactorial dyspnea (41%
ith body mass index 30 kg/m2) and even the absence of
F (25th percentiles for NT-proBNP 139 and 131 pg/ml
n the irbesartan and placebo groups, respectively), compar-
tively well-controlled hypertension at study inclusion (sys-
olic blood pressure 137 mm Hg vs. 136 mm Hg), a high
ate of study drug discontinuation (33%), a very high
roportion of patients on baseline loop or thiazide diuretics
82% vs. 84%), and a high proportion of patients on other
nhibitors of the renin-angiotensin-aldosterone system
baseline treatment and post-randomization initiation). In
nother recent study (the VALIDD [VALsartan In Dia-
tolic Dysfunction] study), it was shown that blood pressure
owering in patients with hypertension and LV diastolic
ysfunction, either with a valsartan-based regimen or a
egimen not including inhibitors of the renin-angiotensin-
ldosterone system, elicited a similar reduction in blood
ressure and an improvement in diastolic relaxation in both
roups (71). Of note, the degree of blood pressure lowering
as much greater than that in the I-PRESERVED trial,
nd this, therefore, suggests that blood pressure control may
e a key factor in determining the response to treatment.
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March 17, 2009:905–18 HF With Normal LVEFowever, it is possible that impaired LV relaxation was not
he main pathophysiologic factor underlying the symptoms
f the patients in the I-PRESERVED trial.
FNEF—the Future?
rial design. Given the symptomatic and prognostic pro-
le of HFNEF and the lack of effective therapy, a clear
mperative remains to elucidate the mechanisms responsible
or HFNEF. To identify the mechanisms that underlie
FNEF, it is more appropriate that patients with HFNEF
re not compared with healthy control subjects, but with
atients with LV hypertrophy/LV diastolic dysfunction
ithout HF. In the design of clinical trials, the role of
ontributing factors such as ischemia, uncontrolled hyper-
ension, and atrial fibrillation must be clearly defined, which
s critical in order to provide a homogeneous cohort in
hich to investigate the effect of specific interventions. In
articular, inducible ischemia must be searched actively with
sensitive method, and the ischemic burden must be
emoved before a patient can be diagnosed with HFNEF.
lthough associated with some limitations, the diagnostic
lgorithm (10) discussed would be a way for a standardized
nd more specific inclusion process.
ossible therapeutic strategies for the treatment of pa-
ients with HFNEF. Assuming that impaired relaxation
nd increased stiffness are major mechanisms underlying
FNEF, it is appropriate that the development of thera-
eutic tools that specifically address these abnormalities
hould be a priority, as recently reviewed (72–74). The
olecular basis of myocardial relaxation has been exten-
ively investigated in both isolated cardiomyocyte and intact
eart preparations (72–74). Active relaxation depends upon
he integrated process of the regulation of diastolic intra-
ellular calcium levels and the uncoupling of the myofila-
ent proteins responsible for cellular contraction. Intracel-
ular calcium control during diastole is critically dependent
pon calcium uptake into the sarcoplasmatic reticulum,
ediated by the sarcoplasmatic/endoplasmatic reticulum
ubstances Evaluated for the Treatment of Patients With HFNEF int Unpublished or Ong ing Clinical Studies (According to NIH Cl
Table 3 Substances Evaluated for the Treatment of Patients Wbut Unpublished or Ongoing Clinical Studies (Accordin
Substance Drug Class
Valsartan Angiotensin-receptor blocker
Aliskiren Selective renin inhibitor
Spironolactone Aldosterone antagonist
Eplerenone Aldosterone antagonist
Sitaxsentan Endothelin receptor A antagonist
Alagebrium Advanced glycation end products cross-links breaker
Atorvastatin Statin
Sildenafil Phosphodiesterase-5 inhibitor
Exenatide Glucagon-like peptide-1 receptor antagonist
Ranolazine Inhibitor of the slowly inactivating component of the ca
Sodium current (late INa channel)
Ivabradine Inhibitor of the “funny” channel (If channel)National Institutes of Health (NIH) Clinical Trials Registry (78).
RAAS  renin-angiotensin-aldosterone system; other abbreviations as in Table 1.alcium adenosine triphosphate (ATP)ase type 2. There is
vidence that low sarcoplasmatic/endoplasmatic reticulum
alcium ATPase type 2 activity is related to impaired
elaxation (75), and gene transfer has been suggested as a
ossible strategy (72,73). Activity of sarcoplasmatic/
ndoplasmatic reticulum calcium ATPase type 2 is closely
egulated by the interacting protein, phospholamban, which
s subject to further control by phosphorylation. Recent
tudies showed that percutaneous delivery of a modified
hospholamban encoded in an adenovirus favorably affected
V function in a large animal model of HF (76). Interven-
ions that specifically target the myofilament proteins have
ot been extensively evaluated, although it is noteworthy
hat a recent study of levosimendan, a myofilament calcium-
ensitizing agent, suggested that it may improve LV dia-
tolic function (77).
Apart from active relaxation, passive LV stiffness, at least
n part due to myocardial fibrosis, is also a key target not
nly in HF with impaired LVEF but also in HFNEF.
here are a number of substances currently evaluated in
linical trials (78) (Table 3) that are thought to favorably
nfluence the disease process of HFNEF by reduction of LV
ypertrophy and myocardial fibrosis and LV diastolic func-
ion. Many of these substances have been successfully used
n other settings. An innovative approach is the use of the
dvanced glycation end products cross-links breaker alage-
rium, which in a pilot study in 23 HFNEF patients
esulted in a reduction in LV mass and an increase in E=
79) and which is currently evaluated in a multicenter study
78). There is intense research on the antifibrotic effects of
nhibitors of growth factors, cytokines, and other signaling
olecules involved in cardiac remodeling in the context of
F with impaired LVEF, some of which have shown
romising results in experimental studies (80). Such strate-
ies might be applicable to HFNEF as well.
The role of the sympathetic nervous system and the
enin-angiotensin-aldosterone system in HFNEF is largely
nknown. However, given that LV hypertrophy is associ-
pletedrials Registry*)
FNEF in Completed
IH Clinical Trials Registry*)
Postulated Targets
RAAS, blood pressure, LVH, LV relaxation
RAAS, blood pressure, LVH, LV relaxation
Collagen turnover, LV relaxation and stiffness
Collagen turnover, LV relaxation and stiffness, endothelial dysfunction
Blood pressure, LVH
Advanced glycation end products, LV relaxation and stiffness
Collagen turnover, LV relaxation and stiffness, vascular function
LVH, LV stiffness, vascular stiffness
Aortic stiffness, LV stiffness
Intracellular calcium, LV relaxation
Heart rate, duration of diastoleComical T
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HF With Normal LVEF March 17, 2009:905–18ted with increased sympathetic activity (81), and more
evere LV hypertrophy seems to be associated with higher
ikelihood of HFNEF (19), the sympathetic nervous system
ay play a role in the pathogenesis of HFNEF as well.
andesartan has been shown to reduce the sympathetic
ctivity measured by iodine-123-meta-iodobenzylguanidine
cintigraphy in patients with HFNEF (defined as LVEF
40%) (82). It remains to be tested whether angiotensin
eceptor blocker therapy improves outcome in carefully
elected HFNEF patients.
Although not explicitly stated in guidelines (5), beta-
lockers and negatively chronotropic calcium-channel blockers
re often proposed for the treatment of HFNEF based on the
ssumption that rate lowering and prolongation of diastole
esults in better LV filling and output (28), and a study
valuating the purely heart rate-lowering agent ivabradine in
FNEF is currently ongoing (78). This concept has been
hallenged by the previously mentioned studies suggesting that
hronotropic incompetence may be an important mechanism
ontributing to exercise intolerance in HFNEF (1,18). How-
ver, the increase in LVEDP during exercise (1,17) with
ssociated dyspnea rather than chronotropic incompetence
ay be the reason to cease exercise at comparatively low heart
ates. One might also argue that chronotropic incompetence
ue to beta receptor desensitization is a feature of HF with
mpaired LVEF as well (83), and these patients benefit from
eta-blocker therapy. Thus, the role of beta-blocker therapy for
he treatment of HFNEF remains to be established. In
ddition, the optimal management of atrial fibrillation in
FNEF is not clear either.
In addition, less recognized factors may play a role in the
athophysiology of HFNEF. HFNEF is associated with
besity (11), which may, in part, be explained by the fact
hat obesity is a surrogate for obstructive sleep apnea.
bstructive sleep apnea is associated with a variety of
ardiovascular abnormalities (84), including increased sym-
athetic nerve activity, hypertension, LV hypertrophy, LV
iastolic dysfunction, and paroxysmal atrial fibrillation.
any of the latter abnormalities can be reduced or even
eversed with continuous positive airway pressure ventila-
ion (84), and there is even some evidence that treatment of
evere obstructive sleep apnea with continuous positive
irway pressure ventilation reduces cardiovascular mortality
85). Data on the effects of continuous positive airway
ressure ventilation on peak oxygen consumption in patients
ith HF and impaired LVEF and concomitant obstructive
leep apnea are conflicting (84). However, due to the
ssociation with hypertension, LV hypertrophy, and atrial
brillation, the role of obstructive sleep apnea in HFNEF
ay be even more important than in HF with impaired
VEF, and treatment may be more effective.
onclusions
FNEF, used as a term to describe a condition associated
ith HF symptoms and normal LVEF, and without obvi-us explanation for the symptoms (e.g., coronary artery
isease, valvular heart disease), is typically associated with
oncentric LV hypertrophy or concentric LV remodeling,
ncreased left atrial size, and LV diastolic dysfunction.
iven that the latter conditions are much more prevalent
han HFNEF, symptoms of HF may be due to the
ontribution of additional mechanisms, including unrecog-
ized ischemia, paroxysmal atrial fibrillation, altered left
trial function, chronotropic incompetence, vascular stiff-
ess, peripheral factors, and others. Further research to
nravel the pathophysiology of HFNEF in very well char-
cterized patients and appropriate control subjects with a
ocus on the exercise response and the neurohumoral axis is
eeded to establish therapeutic strategies.
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